Victory Capital Management Inc. Acquires 101,419 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Victory Capital Management Inc. raised its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 309.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 134,162 shares of the biotechnology company’s stock after acquiring an additional 101,419 shares during the period. Victory Capital Management Inc. owned about 0.29% of United Therapeutics worth $29,501,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of UTHR. Jackson Creek Investment Advisors LLC bought a new stake in shares of United Therapeutics during the 4th quarter valued at approximately $683,000. Van ECK Associates Corp grew its stake in shares of United Therapeutics by 3.9% during the fourth quarter. Van ECK Associates Corp now owns 10,064 shares of the biotechnology company’s stock worth $2,213,000 after buying an additional 379 shares during the last quarter. Watershed Asset Management L.L.C. grew its stake in shares of United Therapeutics by 9.3% during the fourth quarter. Watershed Asset Management L.L.C. now owns 1,275 shares of the biotechnology company’s stock worth $280,000 after buying an additional 108 shares during the last quarter. GAMMA Investing LLC acquired a new position in shares of United Therapeutics during the fourth quarter worth $43,000. Finally, New York State Common Retirement Fund lifted its stake in shares of United Therapeutics by 0.8% in the 4th quarter. New York State Common Retirement Fund now owns 62,709 shares of the biotechnology company’s stock valued at $13,789,000 after acquiring an additional 488 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the completion of the sale, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,880,130.69. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total transaction of $1,291,860.00. Following the completion of the transaction, the executive vice president now directly owns 36,599 shares in the company, valued at approximately $7,880,130.69. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 147,630 shares of company stock valued at $35,089,803. Corporate insiders own 12.50% of the company’s stock.

United Therapeutics Stock Up 2.2 %

Shares of United Therapeutics stock opened at $266.22 on Wednesday. The firm has a market cap of $11.81 billion, a price-to-earnings ratio of 12.59 and a beta of 0.54. The stock’s 50-day moving average is $238.38 and its 200 day moving average is $229.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. United Therapeutics Co. has a one year low of $204.44 and a one year high of $266.65.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping the consensus estimate of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million during the quarter, compared to the consensus estimate of $620.31 million. During the same quarter last year, the firm posted $4.86 EPS. The company’s quarterly revenue was up 33.7% on a year-over-year basis. Equities research analysts anticipate that United Therapeutics Co. will post 23.88 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, April 11th. Wedbush reaffirmed an “outperform” rating and set a $308.00 price target on shares of United Therapeutics in a research note on Thursday, February 22nd. The Goldman Sachs Group boosted their price objective on shares of United Therapeutics from $218.00 to $240.00 and gave the stock a “neutral” rating in a research note on Friday, May 3rd. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, HC Wainwright reiterated a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research report on Thursday, May 2nd. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.